Semaglutide Dosing Guide: Personalized Dose Optimization

Last reviewed: May 20, 2026

Last updated: May 20, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide dosing for weight management typically begins at 0.25 mg weekly and escalates gradually to a target of 2.4 mg weekly over 16–20 weeks. Individual tolerance, metabolic profile, and genetic factors influence how each person responds to dose advancement and efficacy outcomes.

Understanding your personal metabolic context—including genetic predispositions in GLP-1 signaling pathways—can help frame a more informed dosing conversation with your provider. PlexusDx supports precision-wellness approaches that move beyond one-size-fits-all prescribing patterns.

Standard Semaglutide Dosing Schedule and Escalation Protocol

The FDA-approved dosing regimen for semaglutide in weight management follows a predictable escalation pattern. Week 1–4: 0.25 mg weekly. Week 5–8: 0.5 mg weekly. Week 9–12: 1 mg weekly. Week 13–16: 1.7 mg weekly. Week 17+: 2.4 mg weekly. This gradual increase allows the body to adapt and reduces gastrointestinal side effects.

Not all patients tolerate or require the maximum dose. Some achieve meaningful weight loss at 1.7 or 1.0 mg weekly. Provider assessment of individual response, tolerability, and clinical goals determines the optimal maintenance dose. Dose adjustments may take weeks to stabilize.

Dose Escalation Patterns and Individual Response Variables

Response to semaglutide varies considerably across patients. Factors influencing dosing decisions include baseline body mass index, comorbidities, gastrointestinal sensitivity, liver and kidney function, concurrent medications, and genetic variation in GLP-1 receptor expression and signaling. Age and metabolic rate also play roles in dose tolerability.

Dosing Factor	Clinical Consideration
Starting dose	0.25 mg weekly; allows adaptation and baseline tolerability assessment
Escalation timing	Weekly increases every 4 weeks; slower escalation may suit sensitive individuals
Maintenance range	1.0–2.4 mg weekly; many achieve efficacy below maximum dose
Dose hold or reduction	GI side effects, nausea, or appetite loss warrant temporary pause or lower dose
Genetic variation in GLP1R	rs6923761 and other variants may influence receptor sensitivity and dose response
Comorbidity adjustment	Kidney or liver impairment may require dose capping or extended escalation windows

What Research Shows About Efficacy Across Dose Ranges

Clinical trials demonstrate dose-dependent weight loss. The STEP trials showed that 2.4 mg weekly produced approximately 15% mean body weight reduction in adults with obesity. Lower doses (1.0–1.7 mg) achieved approximately 10–13% weight loss. Dose escalation beyond 2.4 mg is not studied for weight management.

Weight loss plateaus typically occur 12–20 weeks after reaching stable maintenance dose. Continued adherence and lifestyle support maintain results. Some patients experience modest weight regain if medication is discontinued, underscoring that dosing decisions connect to long-term management strategy, not short-term goals alone.

Who Should Adjust Dosing and When Provider Guidance Is Essential

Dose adjustments require physician oversight. Patients experiencing severe nausea, vomiting, constipation, or signs of pancreatitis should contact their provider immediately. Slower escalation or temporary dose hold may be appropriate. Individuals with a history of thyroid cancer, medullary thyroid carcinoma, or multiple endocrine neoplasia type 2 cannot use semaglutide. Pregnancy planning requires dose discontinuation.

Compounded semaglutide prescriptions from licensed 503A pharmacies allow flexible dosing tailored to individual tolerance. Regular provider follow-up—typically every 2–4 weeks during escalation, then monthly—ensures dose safety and efficacy. Your provider may reference biomarkers or genetic insights to inform dose escalation strategy.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines variants in GLP1R (rs6923761), GIPR (rs1800437), and FTO (rs9939609) pathways that may provide context for how your body processes GLP-1 signaling. These predispositions may help inform dosing conversations, though genetic variation does not predict exact medication response. Results should be interpreted with a qualified healthcare provider.

Carriers of certain GLP1R and GIPR variants may show differential responses to standard dose escalation. For example, individuals with specific FTO risk alleles often experience stronger appetite suppression at lower doses. The Precision Peptide Genetic Test reveals these genetic predispositions so providers can anticipate individual variability and adjust escalation timelines accordingly.

Combining genetic insights with clinical assessment—liver and kidney function, metabolic baseline, medication interactions—creates a more personalized dosing framework. This approach supports more informed conversations with your provider about optimal dose escalation, side effect management, and long-term adherence strategy for weight management.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.